MULTIPLE MYELOMA WITH FAILED REMISSION
Clinical trials for MULTIPLE MYELOMA WITH FAILED REMISSION explained in plain language.
Never miss a new study
Get alerted when new MULTIPLE MYELOMA WITH FAILED REMISSION trials appear
Sign up with your email to follow new studies for MULTIPLE MYELOMA WITH FAILED REMISSION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Tough-to-Treat myeloma: early safety trial of HPN217 begins
Disease control OngoingThis study is testing a new drug called HPN217 in about 100 people whose multiple myeloma has returned or stopped responding to standard treatments. The main goal is to check the drug's safety and find the best dose. Researchers will also measure how the drug moves through the bo…
Matched conditions: MULTIPLE MYELOMA WITH FAILED REMISSION
Phase: PHASE1 • Sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Online tool aims to empower myeloma patients
Knowledge-focused OngoingThis study tests whether a health technology platform called All4Cure can help people with multiple myeloma become more active in managing their own health. Two hundred participants will fill out surveys about their symptoms and how confident they feel in handling their care. No …
Matched conditions: MULTIPLE MYELOMA WITH FAILED REMISSION
Sponsor: All4Cure • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:51 UTC